Format

Send to

Choose Destination
Br J Haematol. 2015 Aug;170(3):367-71. doi: 10.1111/bjh.13443. Epub 2015 Apr 8.

Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report.

Author information

1
Division of Pediatric Hematology/Oncology, University of Hawaii, Honolulu, HI, USA.
2
Division of Pediatric Hematology/Oncology, Medical City Children's Hospital, Dallas, TX, USA.
3
Department of Biostatistics, University of Nebraska, College of Public Health, Omaha, NE, USA.
4
Division of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, MD, USA.
5
Department of Pathology, University of Utah, Salt Lake City, UT, USA.
6
Section of Pediatric Hematology-Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
7
Department of Cytogenetics, University of Nebraska Medical Center, Omaha, NE, USA.
8
Center for Global Health, NCI, NIH, DHHS, Rockville, MD, USA.
9
Division of Pediatric Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
10
Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
11
Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, NY, USA.
12
Istituto di Ricerca Pediatrico-Fondazione Città della Speranza-University of Padua, Padua, Italy.
13
Department of Medicine, New York Medical College, Valhalla, NY, USA.
14
Department of Pathology, New York Medical College, Valhalla, NY, USA.
15
Department of Microbiology & Immunology, New York Medical College, Valhalla, NY, USA.
16
Department of Cell Biology & Anatomy, New York Medical College, Valhalla, NY, USA.

Abstract

Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.

KEYWORDS:

central nervous system; children; leukaemia

PMID:
25858645
PMCID:
PMC4503484
DOI:
10.1111/bjh.13443
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center